HER2+ 유방암

3개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved3 programs
CGTStandard DatabasestaleNational Cancer Institute (NCI)Phase 2

Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01, Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group, Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR))

Breast Cancer; Cervical Cancer · Breast Cancer

#BreastCancer#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 30Status Discontinued
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 1

Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER, Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor, Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Active
ADCLimited DatastaleShengjing HospitalPhase 2

Next-generation Site-specific human epidermal growth factor receptor 2 (HER2, Next-generation Site-specific human epidermal growth factor receptor 2, Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788))

Breast Neoplasms · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+1
Trials 1Status Recruiting